1
|
Aye M, Jarrahpour A, Haghighijoo Z, Heiran R, Pournejati R, Karbalaei-Heidari HR, Sinou V, Brunel JM, Akkurt M, Özdemir N, Turos E. Novel Benzotriazole-β-lactam Derivatives as Antimalarial Agents: Design, Synthesis, Biological Evaluation and Molecular Docking Studies. Chem Biodivers 2024; 21:e202301745. [PMID: 38192127 DOI: 10.1002/cbdv.202301745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2023] [Revised: 12/28/2023] [Accepted: 01/05/2024] [Indexed: 01/10/2024]
Abstract
Many people around the world suffer from malaria, especially in tropical or subtropical regions. While malaria medications have shown success in treating malaria, there is still a problem with resistance to these drugs. Herein, we designed and synthesized some structurally novel benzotriazole-β-lactams using 2-(1H-benzo[d][1,2,3]triazol-1-yl)acetic acid as a key intermediate. To synthesize the target molecules, the ketene-imine cycloaddition reaction was employed. First, The reaction of 1H-benzo[d][1,2,3]triazole with 2-bromoacetic acid in aqueous sodium hydroxide yielded 2-(1H-benzo[d][1,2,3]triazol-1-yl)acetic acid. Then, the treatment of 2-(1H-benzo[d][1,2,3]triazol-1-yl)acetic acid with tosyl chloride, triethyl amine, and Schiff base provided new β-lactams in good to moderate yields.The formation of all cycloadducts was confirmed by elemental analysis, FT-IR, NMR and mass spectral data. Moreover, X-ray crystallography was used to determine the relative stereochemistry of 4a compound. The in vitro antimalarial activity test was conducted for each compound against P. falciparum K1. The IC50 values ranged from 5.56 to 25.65 μM. A cytotoxicity profile of the compounds at 200 μM final concentration revealed suitable selectivity of the compounds for malaria treatment. Furthermore, the docking study was carried out for each compound into the P. falciparum dihydrofolate reductase enzyme (PfDHFR) binding site to analyze their possible binding orientation in the active site.
Collapse
Affiliation(s)
- Malihe Aye
- Department of Chemistry, College of Sciences, Shiraz University, Shiraz, 71946-84795, Iran
- Department of Civil and Environmental Engineering, Shiraz University, Shiraz, Iran
| | - Aliasghar Jarrahpour
- Department of Chemistry, College of Sciences, Shiraz University, Shiraz, 71946-84795, Iran
| | - Zahra Haghighijoo
- Department of pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, 77555, USA
| | - Roghayeh Heiran
- Estahban Higher Education Center- Shiraz University, Estahban, Iran
| | - Roya Pournejati
- Department of Biology, College of Sciences, Shiraz University, PO Box: 71467-13565, Shiraz, 71454, Iran
| | | | - Veronique Sinou
- Aix Marseille Univ, INSERM, SSA, MCT, Faculté de Pharmacie, 27 bd Jean Moulin, 13385, Marseille, France
| | - Jean Michel Brunel
- Aix Marseille Univ, INSERM, SSA, MCT, Faculté de Pharmacie, 27 bd Jean Moulin, 13385, Marseille, France
| | - Mehmet Akkurt
- Department of Physics, Faculty of Sciences, Erciyes University, 38039, Kayseri, Turkey
| | - Namık Özdemir
- Division of Physics Education, Department of Mathematics and Science Education, Faculty of Education, Ondokuz Mayıs University, TR-55139, Samsun, Turkey
| | - Edward Turos
- Center for Molecular Diversity in Drug Design, Discovery, and Delivery, Department of Chemistry, CHE 207, 4202 East Fowler Avenue, University of South Florida, Tampa, FL 33620, USA
| |
Collapse
|
2
|
Kaczor A, Witek K, Podlewska S, Sinou V, Czekajewska J, Żesławska E, Doroz-Płonka A, Lubelska A, Latacz G, Nitek W, Bischoff M, Alibert S, Pagès JM, Jacob C, Karczewska E, Bolla JM, Handzlik J. Molecular Insights into an Antibiotic Enhancer Action of New Morpholine-Containing 5-Arylideneimidazolones in the Fight against MDR Bacteria. Int J Mol Sci 2021; 22:ijms22042062. [PMID: 33669790 PMCID: PMC7922564 DOI: 10.3390/ijms22042062] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2021] [Revised: 02/11/2021] [Accepted: 02/13/2021] [Indexed: 01/21/2023] Open
Abstract
In the search for an effective strategy to overcome antimicrobial resistance, a series of new morpholine-containing 5-arylideneimidazolones differing within either the amine moiety or at position five of imidazolones was explored as potential antibiotic adjuvants against Gram-positive and Gram-negative bacteria. Compounds (7–23) were tested for oxacillin adjuvant properties in the Methicillin-susceptible S. aureus (MSSA) strain ATCC 25923 and Methicillin-resistant S. aureus MRSA 19449. Compounds 14–16 were tested additionally in combination with various antibiotics. Molecular modelling was performed to assess potential mechanism of action. Microdilution and real-time efflux (RTE) assays were carried out in strains of K. aerogenes to determine the potential of compounds 7–23 to block the multidrug efflux pump AcrAB-TolC. Drug-like properties were determined experimentally. Two compounds (10, 15) containing non-condensed aromatic rings, significantly reduced oxacillin MICs in MRSA 19449, while 15 additionally enhanced the effectiveness of ampicillin. Results of molecular modelling confirmed the interaction with the allosteric site of PBP2a as a probable MDR-reversing mechanism. In RTE, the compounds inhibited AcrAB-TolC even to 90% (19). The 4-phenylbenzylidene derivative (15) demonstrated significant MDR-reversal “dual action” for β-lactam antibiotics in MRSA and inhibited AcrAB-TolC in K. aerogenes. 15 displayed also satisfied solubility and safety towards CYP3A4 in vitro.
Collapse
Affiliation(s)
- Aneta Kaczor
- Department of Technology and Biotechnology of Drugs, Jagiellonian University, Medical College, ul. Medyczna 9, 30-688 Krakow, Poland; (A.K.); (K.W.); (S.P.); (A.D.-P.); (A.L.); (G.L.)
| | - Karolina Witek
- Department of Technology and Biotechnology of Drugs, Jagiellonian University, Medical College, ul. Medyczna 9, 30-688 Krakow, Poland; (A.K.); (K.W.); (S.P.); (A.D.-P.); (A.L.); (G.L.)
- Department of Pharmaceutical Microbiology, Jagiellonian University, Medical College, ul. Medyczna 9, 30-688 Krakow, Poland; (J.C.); (E.K.)
- UMR_MD1, U-1261, Aix Marseille Univ, INSERM, SSA, MCT, Faculté de Pharmacie, 27 Bd Jean Moulin, 13005 Marseille, France; (V.S.); (S.A.); (J.-M.P.); (J.-M.B.)
- Institute for Medical Microbiology and Hygiene, Saarland University, D-66421 Homburg/Saar, Germany;
- Division of Bioorganic Chemistry, School of Pharmacy, Saarland University, Campus B 2.1, D-66123 Saarbruecken, Germany;
| | - Sabina Podlewska
- Department of Technology and Biotechnology of Drugs, Jagiellonian University, Medical College, ul. Medyczna 9, 30-688 Krakow, Poland; (A.K.); (K.W.); (S.P.); (A.D.-P.); (A.L.); (G.L.)
- Maj Institute of Pharmacology, Polish Academy of Sciences, Department of Medicinal Chemistry, ul. Smętna 12, 31-343 Krakow, Poland
| | - Veronique Sinou
- UMR_MD1, U-1261, Aix Marseille Univ, INSERM, SSA, MCT, Faculté de Pharmacie, 27 Bd Jean Moulin, 13005 Marseille, France; (V.S.); (S.A.); (J.-M.P.); (J.-M.B.)
| | - Joanna Czekajewska
- Department of Pharmaceutical Microbiology, Jagiellonian University, Medical College, ul. Medyczna 9, 30-688 Krakow, Poland; (J.C.); (E.K.)
| | - Ewa Żesławska
- Pedagogical University of Cracow, Institute of Biology, ul. Podchorążych 2, 30-084 Krakow, Poland;
| | - Agata Doroz-Płonka
- Department of Technology and Biotechnology of Drugs, Jagiellonian University, Medical College, ul. Medyczna 9, 30-688 Krakow, Poland; (A.K.); (K.W.); (S.P.); (A.D.-P.); (A.L.); (G.L.)
| | - Annamaria Lubelska
- Department of Technology and Biotechnology of Drugs, Jagiellonian University, Medical College, ul. Medyczna 9, 30-688 Krakow, Poland; (A.K.); (K.W.); (S.P.); (A.D.-P.); (A.L.); (G.L.)
| | - Gniewomir Latacz
- Department of Technology and Biotechnology of Drugs, Jagiellonian University, Medical College, ul. Medyczna 9, 30-688 Krakow, Poland; (A.K.); (K.W.); (S.P.); (A.D.-P.); (A.L.); (G.L.)
| | - Wojciech Nitek
- Faculty of Chemistry, Jagiellonian University, ul. Gronostajowa 2, 30-387 Krakow, Poland;
| | - Markus Bischoff
- Institute for Medical Microbiology and Hygiene, Saarland University, D-66421 Homburg/Saar, Germany;
| | - Sandrine Alibert
- UMR_MD1, U-1261, Aix Marseille Univ, INSERM, SSA, MCT, Faculté de Pharmacie, 27 Bd Jean Moulin, 13005 Marseille, France; (V.S.); (S.A.); (J.-M.P.); (J.-M.B.)
| | - Jean-Marie Pagès
- UMR_MD1, U-1261, Aix Marseille Univ, INSERM, SSA, MCT, Faculté de Pharmacie, 27 Bd Jean Moulin, 13005 Marseille, France; (V.S.); (S.A.); (J.-M.P.); (J.-M.B.)
| | - Claus Jacob
- Division of Bioorganic Chemistry, School of Pharmacy, Saarland University, Campus B 2.1, D-66123 Saarbruecken, Germany;
| | - Elżbieta Karczewska
- Department of Pharmaceutical Microbiology, Jagiellonian University, Medical College, ul. Medyczna 9, 30-688 Krakow, Poland; (J.C.); (E.K.)
| | - Jean-Michel Bolla
- UMR_MD1, U-1261, Aix Marseille Univ, INSERM, SSA, MCT, Faculté de Pharmacie, 27 Bd Jean Moulin, 13005 Marseille, France; (V.S.); (S.A.); (J.-M.P.); (J.-M.B.)
| | - Jadwiga Handzlik
- Department of Technology and Biotechnology of Drugs, Jagiellonian University, Medical College, ul. Medyczna 9, 30-688 Krakow, Poland; (A.K.); (K.W.); (S.P.); (A.D.-P.); (A.L.); (G.L.)
- Correspondence: ; Tel.: +48 12 620-55-80
| |
Collapse
|
3
|
Mandoko PN, Mbongi DM, Mumba DN, Bi Shamamba SK, Tshilolo LM, Muyembe JJ, Parzy D, Sinou V. Evaluation of the application of national malaria treatment guidelines in private pharmacies in a rural area in the Democratic Republic of Congo. Med Sante Trop 2019; 29:392-398. [PMID: 31884993 DOI: 10.1684/mst.2019.0925] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
In the Democratic Republic of the Congo, the first recourse in case of suspected malaria in the health system is the private pharmacy sector. This study was therefore designed to assess private provider adherence to national case management guidelines in Kimpese, a rural area of Central Kongo province. A descriptive cross-sectional survey of 103 pharmacies took place in March 2016. The study included 97 pharmacies. The artemether-lumefantrine combination recommended as the first-line treatment for uncomplicated P. falciparum malaria was available in 100% of pharmacies but only 3% stocked quality-assured medicines. The sulfadoxine-pyrimethamine recommended for intermittent preventive treatment of malaria in pregnant women and quinine, which is no longer part of national policy, were widely available (>97.0% of pharmacies). Among providers, fewer than 20% were aware of the national malaria treatment guidelines. The main reasons for non-adherence to national guidelines among private dispensers was the high cost (up to 10 times more expensive than sulfadoxine-pyrimethamine treatment) and adverse effects of artemisinin-based combination therapies. Governmental interventions to improve private sector engagement in implementation of the national guidelines and to prevent the spread of ineffective and non-quality assured antimalarial medicines must be intensified.
Collapse
Affiliation(s)
- P N Mandoko
- Institut national de recherche biomédicale, Kinshasa, Congo, RDC
| | - D M Mbongi
- Centre de formation et d'appui sanitaire, Kinshasa, Congo, RDC
| | - D N Mumba
- Institut national de recherche biomédicale, Kinshasa, Congo, RDC
| | - S K Bi Shamamba
- Institut national de recherche biomédicale, Kinshasa, Congo, RDC
| | - L M Tshilolo
- Centre de formation et d'appui sanitaire, Kinshasa, Congo, RDC
| | - J J Muyembe
- Institut national de recherche biomédicale, Kinshasa, Congo, RDC
| | | | - V Sinou
- Inserm, SSA, IRBA, MCT, Aix-Marseille Université, Marseille, France
| |
Collapse
|
4
|
Nkoli Mandoko P, Sinou V, Moke Mbongi D, Ngoyi Mumba D, Kahunu Mesia G, Losimba Likwela J, Bi Shamamba Karhemere S, Muepu Tshilolo L, Tamfum Muyembe JJ, Parzy D. Access to artemisinin-based combination therapies and other anti-malarial drugs in Kinshasa. Med Mal Infect 2018. [DOI: 10.1016/j.medmal.2018.02.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
5
|
Rad JA, Jarrahpour A, Latour C, Sinou V, Brunel JM, Zgou H, Mabkhot Y, Hadda TB, Turos E. Synthesis and antimicrobial/antimalarial activities of novel naphthalimido trans-β-lactam derivatives. Med Chem Res 2017. [DOI: 10.1007/s00044-017-1920-z] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
6
|
Sinou V, Fiot J, Taudon N, Mosnier J, Martelloni M, Bun SS, Parzy D, Ollivier E. High-performance liquid chromatographic method for the quantification of Mitragyna inermis alkaloids in order to perform pharmacokinetic studies. J Sep Sci 2010; 33:1863-9. [PMID: 20437411 DOI: 10.1002/jssc.201000008] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
In Africa, Mitragyna inermis (Willd.) O. Kuntze (Rubiaceae) is commonly used in traditional medicine to treat malaria. Antimalarial activity is mostly due to the hydromethanolic extract of M. inermis leaves and especially to the main alkaloids, uncarine D and isorhynchophilline. In the present study, we describe for the first time an HPLC method for the simultaneous quantification of uncarine D and isorhynchophylline in biological matrices. SPE was used to extract the components and the internal standard naphthalene from human and pig plasma samples. Chromatographic separation was performed on a C-18 reversed column at a flow rate of 1 mL/min, using methanol-phosphate buffer (10:90, pH 7), as a mobile phase. Good linearity was observed over the concentration ranges of 0.0662-3.31 microg/mL for uncarine D and 0.0476-2.38 microg/mL for isorynchophylline. The precision was less than 12% and the accuracy was from 86 to 107% without any discrepancy between the two species. Uncarine D and isorhynchophylline recoveries were over 80%. These results allowed the quantification of both uncarine D and isorhynchophylline in pig plasma after intravenous administration of M. inermis extract.
Collapse
Affiliation(s)
- Veronique Sinou
- UMR-MD3 Relations Hôte-Parasite, Pharmacologie et Thérapeutique, Unité de Recherche en Physiopathologie et Pharmacologie Parasitaire, Université de la Méditerranée, Institut de Recherche Biomédicale des Armées, Parc du Pharo, Marseille, France.
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Sinou V, Malaika LTM, Taudon N, Lwango R, Alegre SS, Bertaux L, Sugnaux F, Parzy D, Benakis A. Pharmacokinetics and pharmacodynamics of a new ACT formulation: Artesunate/Amodiaquine (TRIMALACT) following oral administration in African malaria patients. Eur J Drug Metab Pharmacokinet 2010; 34:133-42. [PMID: 20166428 DOI: 10.1007/bf03191163] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
A new fixed-dose combination of artesunate (AS) plus amodiaquine (AQ) (TRIMALACT) was recently developed for the treatment of uncomplicated falciparum malaria. The originality of this combination lies in its galenic formulation which consists of a three-layer tablet with two layers containing each of the active ingredients, i.e. AS and AQ, and these are separated by a middle layer containing an antioxidant compound. To evaluate the efficacy and tolerability of this combination, adults with uncomplicated malaria received three administrations of two tablets (100:300 mg AS/AQ) in a 24-h interval, in Democratic Republic of Congo. Parasitemia and fever were measured and the plasma levels of parent compounds and metabolites [dihydroartemisinin (DHA) and monodesethylamodiaquine (MdAQ)] were determined by high-performance liquid chromatography. In addition, we determined the prevalence of molecular markers of resistance to chloroquine (CQ) and sulfadoxine/pyrimethamine (SP). The AS/AQ combination TRIMALACT demonstrated a good efficacy resulting in an excellent clinical and parasitological response rate of 100% after correction for PCR results. Treatment regimen was well tolerated. The main disposition parameters to AS+AQ were: for DHA, AUC = 632 +/- 475 ng h/ml and Cmax = 432 +/- 325 ng/ml, and for MdAQ = 14268 +/- 4114 ng h/ml and Cmax = 336 +/- 225 ng/ml (mean +/- standard deviation). Parasite genotyping show high frequencies of molecular SP- and CQ-resistance markers with more 80% of the samples showing more than three mutations linked to SP resistance and 93.48% carrying parasite with the CQ-resistant haplotype. This study shows that the AS/AQ combination TRIMALACT is safe and effective in the treatment of highly drug-resistant falciparum malaria.
Collapse
Affiliation(s)
- V Sinou
- UMR-MD3, Faculty of Pharmacy, University of Méditerranée, Institute of Tropical Medicine of the French Army Forces, Marseille, France
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Vo TKD, Bigot P, Gazin P, Sinou V, De Pina JJ, Huynh DC, Fumoux F, Parzy D. Evaluation of a real-time PCR assay for malaria diagnosis in patients from Vietnam and in returned travellers. Trans R Soc Trop Med Hyg 2006; 101:422-8. [PMID: 17150235 DOI: 10.1016/j.trstmh.2006.09.004] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2006] [Revised: 08/04/2006] [Accepted: 09/13/2006] [Indexed: 11/20/2022] Open
Abstract
Real-time PCR diagnosis of malaria has advantages over traditional microscopic methods, especially when parasitaemia is low and when dealing with mixed infections. We have developed a new real-time PCR with specific genes in each Plasmodium species present only in one copy to identify the four pathogenic Plasmodium spp. for humans. The sensitivity was less than 25 parasites/microl. No cross-hybridisation was observed with human DNA or among the four Plasmodium spp. Using LightCycler PCR and conventional microscopy, we compared the diagnosis of malaria in patients from Vietnam and in returned European travellers with suspicion of malaria. In patients from Vietnam with suspicion of malaria, one mixed infection was observed by PCR only; the remaining data (54 of 55 patients) correlated with microscopy. In 79 patients without symptoms, low parasitaemia was detected in 7 samples by microscopy and in 16 samples by PCR. In returned travellers, PCR results were correlated with microscopy for all four species in 48 of 56 samples. The eight discrepant results were resolved in favour of real-time PCR diagnosis. This new real-time PCR is a rapid, accurate and efficient method for malaria diagnosis in returned travellers as well as for epidemiological studies or antimalarial efficiency trials in the field.
Collapse
Affiliation(s)
- Thi Kim Duy Vo
- Université de la Méditerranée, EA 864, IFR 48, Marseille, France; University of Hue, 20 Le Loi, Hue, Vietnam
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Hammadi A, Ramiandrasoa F, Sinou V, Rogier C, Fusai T, Le Bras J, Parzy D, Kunesch G, Pradines B. Cellular uptake of a catechol iron chelator and chloroquine into Plasmodium falciparum infected erythrocytes. Biochem Pharmacol 2003; 65:1351-60. [PMID: 12694876 DOI: 10.1016/s0006-2952(03)00042-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Our study demonstrates the capacity of FR160, a catechol iron chelator, to reach and accumulate into infected Plasmodium falciparum erythrocytes and parasites (cellular accumulation ratio between 12 and 43). Steady-state FR160 accumulation is obtained after 2 hr of exposure. After 2 hr exposure, it reaches intracellular levels that are 4- to 10-fold higher in infected red blood cells than those attained in normal erythrocytes. There is quite a good correlation between the accumulation of chloroquine and FR160 in the different strains (r=0.939) and in the IC(50) values (r=0.719). In contrast, the accumulation of FR160 and its activity is poorly correlated (r=0.500), suggesting that activity of FR160 may be independent of its penetration into infected erythrocytes. The mechanism of accumulation is yet unknown but based on inhibitor studies, the uptake of FR160 seems to be not associated with the calcium pump or channel, the potassium channel or the Na(+)/H(+) exchanger. Combinations of FR160 with verapamil, diltiazem, clotrimazole, amiloride, diazoxide, 4-aminopyridine, and picrotoxin should be avoided (antagonistic effects). The potent in vitro activity of FR160 on chloroquine-resistant strains or isolates, its lower toxicity against Vero cells, its mechanisms of action, its capacity to reach rapidly and accumulate into infected erythrocytes suggest that FR160 holds much promise as a new structural lead and effective antimalarial agent or at least a promising adjuvant in treatment of malaria.
Collapse
Affiliation(s)
- Akli Hammadi
- Unité d'Enseignement Radioprotection, Biologie et Médecine, Institut National des Sciences et Techniques Nucléaires, Centre d'Energie Atomique de Saclay, Gif-sur-Yvette, France
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Nealon C, Dzeing A, Müller-Römer U, Planche T, Sinou V, Kombila M, Kremsner PG, Parzy D, Krishna S. Intramuscular bioavailability and clinical efficacy of artesunate in gabonese children with severe malaria. Antimicrob Agents Chemother 2002; 46:3933-9. [PMID: 12435698 PMCID: PMC132755 DOI: 10.1128/aac.46.12.3933-3939.2002] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Artesunate (ARS) is a water-soluble artemisinin derivative that is a potential alternative to quinine for the treatment of severe childhood malaria. We studied the pharmacokinetics and bioavailability of ARS given by the intramuscular (i.m.) route in an open crossover study design. Fourteen children were randomized to receive intravenous (i.v.) ARS in a loading dose (2.4 mg/kg of body weight) followed 12 h later by an i.m. dose (1.2 mg/kg) (group I), and 14 children were randomized to receive i.m. ARS (2.4 mg/kg) followed by an i.v. dose of ARS (1.2 mg/kg) (group II). We carried out a two-compartment analysis of ARS and dihydroartemisinin (DHA; the principal antimalarial metabolite) levels in 21 children (groups I and II combined). Absorption of i.m. ARS was rapid, with the maximum concentration of DHA in serum being achieved in less than 1 h in most children (median time to the maximum concentration of drug in serum, 35.1 min; range, 10.8 to 71.9 min). The absolute bioavailability of DHA was a median of 86.4% (range, 11.4 to 462.1%), the median steady-state volume of distribution was 1.3 liters/kg (range, 0.5 to 7.9 liters/kg), and the median clearance was 0.028 liters/kg/min (range, 0.001 to 1.58 liters/kg/min). There were no major adverse events attributable to ARS. Parasite clearance kinetics were comparable between the two treatment groups. These results support the use of i.m. ARS in children with severe malaria.
Collapse
Affiliation(s)
- Claire Nealon
- Department of Infectious Diseases, St. George's Hospital Medical School, London SW17 ORE, United Kingdom
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Parzy D, Rogier C, Keundjian A, Fusaï T, Pradines B, Sinou V. [Malaria research at the IMTSSA le Pharo]. Med Trop (Mars) 2002; 61:11-4. [PMID: 11584650] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Affiliation(s)
- D Parzy
- Unité de Parasitologie, Institut de médecine tropicale du Service de santé des armées.
| | | | | | | | | | | |
Collapse
|
12
|
Pradines B, Fusai T, Rogier C, Keundjian A, Sinou V, Merckx A, Mosnier J, Daries W, Torrentino M, Parzy D. [Prevention and treatment of malaria: in vitro evaluation of new compounds]. Ann Pharm Fr 2001; 59:319-23. [PMID: 11787425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
One of the current options for reducing the morbidity and mortality of malaria are chemoprophylaxis and chemotherapy. For this reason, the increasing prevalence of strains of Plasmodium falciparum resistant to chloroquine and other antimalarial drugs poses a serious problem for control of malaria. There is an urgent need to find and develop novel compounds and to identify novel chemotherapeutic targets. Different approaches to discover new compounds are presented from examples of molecules studied in the Tropical Medicine Institute of the French Army Health Service (IMTSSA) evaluation against isolates of compounds in pharmaceutical development in collaboration with pharmaceuticals (pyronaridine, benflumetol, ferrochloroquine), screening of molecules which are still registered for other pathologies (antibiotics), screening of new synthesized compounds (artemisinin derivatives) and identification of parasitical targets and essential metabolic ways for parasite, and identification of molecules acting on these targets (reversal of resistance to chloroquine, iron chelators).
Collapse
Affiliation(s)
- B Pradines
- Unité de Parasitologie, Institut de Médecine Tropicale du Service de Santé des Armées, Bd C. Livon, Parc le Pharo, BP 46, F13998 Marseille Armées
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Grellier P, Sinou V, Garreau-de Loubresse N, Bylèn E, Boulard Y, Schrével J. Selective and reversible effects of vinca alkaloids on Trypanosoma cruzi epimastigote forms: blockage of cytokinesis without inhibition of the organelle duplication. Cell Motil Cytoskeleton 2000; 42:36-47. [PMID: 9915583 DOI: 10.1002/(sici)1097-0169(1999)42:1<36::aid-cm4>3.0.co;2-g] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Vinca alkaloids, vincristine and vinblastine, produce differential effects on the cell division of Trypanosoma cruzi epimastigote forms depending on drug concentrations. These effects are related to different microtubule-based mechanisms. For 15 microM vinblastine and 50 microM vincristine, the drugs inhibit both nuclear division and cytokinesis, and affect cell shape. At 3 microM vinblastine and 10 microM vincristine, however, cytokinesis is inhibited without major effect on the progression of the cell cycle; this yields giant cells having multiple nuclei, kinetoplasts and flagella. Cultures maintained over 1 week with daily drug replacement produced cells with more than 16 nuclei and 24 kinetoplasts, indicating that an equivalent of a fifth cell cycle was initiated. The ultrastructure of the multinucleate cells showed a basic organization closely similar to that of trypanosomes. Cytokinesis inhibition by vinca alkaloids seems to result from modulations of interactions between microtubules and associated proteins, rather than from an inhibition of microtubule dynamics as is usually proposed for vinca alkaloids. Cytokinesis inhibition is reversible: after removing the drug, epimastigotes emerge from the multinucleate cells. The emerging process follows a precise axis and polarity which are determined by the position of the flagellum/kinetoplast complex. This region could play an essential role in cell morphogenesis since zoids (cells without a nucleus) are frequently observed.
Collapse
Affiliation(s)
- P Grellier
- Laboratoire de Biologie Parasitaire et Chimiothérapie, EP CNRS 1790, Muséum National d'Histoire Naturelle, Paris, France
| | | | | | | | | | | |
Collapse
|
14
|
Grellier P, Blum J, Santana J, Bylèn E, Mouray E, Sinou V, Teixeira AR, Schrével J. Involvement of calyculin A-sensitive phosphatase(s) in the differentiation of Trypanosoma cruzi trypomastigotes to amastigotes. Mol Biochem Parasitol 1999; 98:239-52. [PMID: 10080392 DOI: 10.1016/s0166-6851(98)00172-8] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Differentiation of the non-dividing trypomastigote form of Trypanosoma cruzi, the causative agent of Chagas disease, to the dividing amastigote form normally occurs in cytoplasm of infected cells. Here we show that calyculin A. a potent inhibitor of protein phosphatases 1 and 2A, induces at pH 7.5 extracellular transformation of long slender trypomastigotes to round amastigote-like forms which acquire characteristic features observed after the normal differentiation process: repositioning and structural changes of the kinetoplast, release of surface neuraminidase, and expression of amastigote-specific epitopes. Calyculin A inhibits parasite phosphatases and changes in the phosphorylation of specific proteins occur during the transformation process. As an exposure of trypomastigotes to calyculin A concentrations as low as 1 nM and for only 1-2 h is sufficient to induce transformation, the inhibition of calyculin A-sensitive phosphatase(s) appears to play a major role in initiating the trypomastigote differentiation.
Collapse
Affiliation(s)
- P Grellier
- Laboratoire de Biologie Parasitaire, EP CNRS 1790 Biologie et Evolution des Parasites, Muséum National d'Histoire Naturelle, Paris, France.
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Sinou V, Boulard Y, Grellier P, Schrevel J. Host cell and malarial targets for docetaxel (Taxotere) during the erythrocytic development of Plasmodium falciparum. J Eukaryot Microbiol 1998; 45:171-83. [PMID: 9561771 DOI: 10.1111/j.1550-7408.1998.tb04522.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The microtubular stabilizing agent docetaxel (Taxotere) is known to inhibit the intraerythrocytic development of Plasmodium falciparum. To investigate the mechanism(s) of inhibition, we analyzed the structural organization of the mitotic spindle by immunofluorescence and electron microscopy. When 30 microM docetaxel was applied for five hours on ring forms, alterations in the mitotic spindles leading to abnormal nuclear divisions were observed. At the trophozoite- and schizont-stage, docetaxel pulses prevent mitosis by stabilizing microtubular structures associated with the mitotic apparatus, giving abnormal spindles. However, this inhibition did not interfere with parasite DNA synthesis indicating the absence of a checkpoint that couples exit from mitosis with proper spindle assembly as observed in higher eukaryotic cells. In parallel, intraerythrocytic concentration of docetaxel was measured in parasitized erythrocytes, after incubation of cells with 3H-docetaxel for five hours. It was found to be 14-fold increased at the ring-stage of infected erythrocytes compared to normal ones, 170-fold increased at the trophozoite-stage and 1,500-fold increased at the schizont-stage. Our data show that, even though the overall intracellular concentration of docetaxel is low in docetaxel-pulsed rings, the agent might be sufficient to disturb the spindle organization. However, the existence of targets for docetaxel other than mitotic spindle microtubules, i.e. erythrocyte membrane components could interfere with mitotic spindle formation.
Collapse
Affiliation(s)
- V Sinou
- Laboratoire de Biologie Parasitaire et Chimiothérapie, ERS-CNRS 156, Muséum National d'Histoire Naturelle, Paris, France
| | | | | | | |
Collapse
|
16
|
Abstract
Blood-parasite protozoa are causative agents of some of the major tropical or infectious diseases for humans and animals, such as Plasmodium for malaria (about 270 million infected people), Trypanosoma cruzi for Chagas' disease (about 18-20 million individuals), African trypanosomes for human and bovine trypanosomiasis, and Babesia for cattle and dogs. The absence of efficient vaccines against these diseases, the absence or the high toxicity of the few drugs against American and African trypanosomiasis, and the emergence of chemoresistance against Plasmodium falciparum emphasize the necessity to propose new antiparasitic strategies. Among these strategies, the biological strategy is based on the identification of key molecules for parasite development such that structural analogs can be designed that are parasite-specific or sufficiently inactive for the host. This requires a careful biochemical analysis of each step of the parasite life cycle. For blood-parasite protozoa, the lipid metabolism required for membrane biogenesis, antimicrotubular drugs or inhibitors of the mitotic spindle, and drug targeting offer new trends in chemotherapy against Plasmodium, Babesia, and trypanosomes.
Collapse
Affiliation(s)
- J Schrével
- Muséum National d'Histoire Naturelle, Laboratoire de Biologie Parasitaire Chimiothérapie, Paris, France
| | | | | | | | | | | |
Collapse
|
17
|
Sinou V, Grellier P, Schrevel J. In vitro and in vivo inhibition of erythrocytic development of malarial parasites by docetaxel. Antimicrob Agents Chemother 1996; 40:358-61. [PMID: 8834880 PMCID: PMC163116 DOI: 10.1128/aac.40.2.358] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
The stage-dependent susceptibility of Plasmodium falciparum to a short exposure to docetaxel (Taxotere) was evaluated by subjecting ring-infected, trophozoite-infected, and schizont-infected erythrocytes to a 5-h exposure to various concentrations of the drug. The schizont stage was shown to be the most sensitive stage; an inhibition of more than 60% of parasite development was observed at 10 nM. At this drug concentration, the development of the younger ring and trophozoite forms was unaffected. The in vivo antimalarial activity of docetaxel against the development in blood of old trophozoites of a species that causes malaria in rodents, Plasmodium vinckei petteri, was evaluated in IOPS-OF1 mice. Two tests were performed: the 4-day suppressive test, as described by Peters (W. Peters, p. 145-273, in Chemotherapy, and Drug Resistance in Malaria, vol. 1, 1987), and the effects of a single injection of docetaxel after inoculation of the parasites. A single injection of docetaxel at 40 mg/kg of body weight was sufficient to reduce drastically the level of parasitemia; 90% inhibition of the development of parasites in blood was observed 5 days after drug injection. This program avoided the toxicity observed when mice were treated with four injections of docetaxel. The possibility of using a single bolus of taxoids to treat malaria infections is discussed.
Collapse
Affiliation(s)
- V Sinou
- Laboratoire de Biologie Parasitaire, Muséum National d'Histoire Naturelle, Paris, France
| | | | | |
Collapse
|
18
|
Schrével J, Sinou V, Grellier P, Frappier F, Guénard D, Potier P. Interactions between docetaxel (Taxotere) and Plasmodium falciparum-infected erythrocytes. Proc Natl Acad Sci U S A 1994; 91:8472-6. [PMID: 7915841 PMCID: PMC44628 DOI: 10.1073/pnas.91.18.8472] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
Taxotere (docetaxel) inhibits Plasmodium falciparum erythrocytic development in vitro at nanomolar concentrations, both in chloroquine-sensitive (F32/Tanzania) and chloroquine-resistant (FcB1/Colombia, FcR3/Gambia) strains. The dose-response assays performed on asynchronous cultures during 42 hr showed clear biphasic curves with a plateau from 50 microM to 10 nM and a single sigmoid curve with a concentration inhibiting 50% of growth (IC50) of 3-6 nM observed after a 72-hr incubation. Addition of Taxotere to different stages of FcB1 revealed two types of targets: one type on ring/trophozoite-infected erythrocytes (RBCs), at the micromolar level, and another type on schizont-infected RBCs with Taxotere at micromolar concentrations inhibited the merozoite invasion of erythrocytes and parasite growth. These Taxotere-RBC interactions were stable, at least for 1 day. Pulse experiments of 5 hr with Taxotere efficiently inhibit parasite development regardless of the period of the parasite's erythrocytic life cycle. However, different cellular effects were obtained depending upon periods of drug incubations. The inhibition of P. falciparum development by Taxotere should provide additional strategies to block parasite development.
Collapse
Affiliation(s)
- J Schrével
- Laboratoire de Biologie Parasitaire et Chimiothérapie, Centre National de la Recherche Scientifique Unité de Recherche Associée 114, Muséum National d'Histoire Naturelle, Paris, France
| | | | | | | | | | | |
Collapse
|